Randomized, Controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of WRAIR's AMA-1 Malaria Vaccine (FMP2.1) Adjuvanted in GSKBio's AS02A Vs. Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali.

Trial Profile

Randomized, Controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of WRAIR's AMA-1 Malaria Vaccine (FMP2.1) Adjuvanted in GSKBio's AS02A Vs. Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Feb 2016

At a glance

  • Drugs AS02 (Primary) ; Malaria vaccine (Primary) ; Rabies vaccine
  • Indications Falciparum malaria; Rabies
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 14 Oct 2011 Additional lead trial centers identified as reported by ClinicalTrials.gov.
    • 04 Feb 2009 Actual patient numbers (100) added as reported by ClinicalTrials.gov.
    • 04 Sep 2008 Actual start date changed from Nov 2006 to Oct 2006 as reported by Clinicaltrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top